Unknown

Dataset Information

0

Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.


ABSTRACT: HIV-1 protease inhibitors (PIs) exhibit different protein binding affinities and achieve variable plasma and tissue concentrations. Degree of plasma protein binding may impact central nervous system penetration. This cross-sectional study assessed cerebrospinal fluid (CSF) unbound PI concentrations, HIV-1 RNA, and neopterin levels in subjects receiving either ritonavir-boosted darunavir (DRV), 95% plasma protein bound, or atazanavir (ATV), 86% bound. Unbound PI trough concentrations were measured using rapid equilibrium dialysis and liquid chromatography/tandem mass spectrometry. Plasma and CSF HIV-1 RNA and neopterin were measured by Ampliprep/COBAS® Taqman® 2.0 assay (Roche) and enzyme-linked immunosorbent assay (ALPCO), respectively. CSF/plasma unbound drug concentration ratio was higher for ATV, 0.09 [95% confidence interval (CI) 0.06-0.12] than DRV, 0.04 (95%CI 0.03-0.06). Unbound CSF concentrations were lower than protein adjusted wild-type inhibitory concentration-50 (IC50 ) in all ATV and 1 DRV-treated subjects (P?

SUBMITTER: Delille CA 

PROVIDER: S-EPMC4396178 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.

Delille Cecile A CA   Pruett Sarah T ST   Marconi Vincent C VC   Lennox Jeffrey L JL   Armstrong Wendy S WS   Arrendale Richard F RF   Sheth Anandi N AN   Easley Kirk A KA   Acosta Edward P EP   Vunnava Aswani A   Ofotokun Ighovwerha I  

Journal of clinical pharmacology 20140408 9


HIV-1 protease inhibitors (PIs) exhibit different protein binding affinities and achieve variable plasma and tissue concentrations. Degree of plasma protein binding may impact central nervous system penetration. This cross-sectional study assessed cerebrospinal fluid (CSF) unbound PI concentrations, HIV-1 RNA, and neopterin levels in subjects receiving either ritonavir-boosted darunavir (DRV), 95% plasma protein bound, or atazanavir (ATV), 86% bound. Unbound PI trough concentrations were measure  ...[more]

Similar Datasets

| S-EPMC3993270 | biostudies-literature
| S-EPMC6799853 | biostudies-literature
| S-EPMC10790009 | biostudies-literature
| S-EPMC7694838 | biostudies-literature
| S-EPMC4834603 | biostudies-literature
| S-EPMC4751867 | biostudies-literature
| PRJNA856347 | ENA
| S-EPMC3572463 | biostudies-literature
| S-EPMC554085 | biostudies-literature
| S-EPMC6506501 | biostudies-literature